Editorial Comment
Is Thrombolytic Therapy Striking Out in Unstable Angina?
David Waters, MD, and Jules Y.T. Lam, MD T hrombolytic therapy for unstable angina appeared to be the next logical step forward on the basis of the following facts. When given early in the acute phase of myocardial infarction, thrombolytic therapy substantially reduces mortality and preserves ventricular function. An open artery, as opposed to a total occlusion, provides additional independent benefit, but reocclusion and thus reinfarction remain a lingering problem during the early phase after treatment. The pathophysiologies of unstable angina and myocardial infarction are similar: plaque rupture leads to an intracoronary mural thrombus that reduces coronary flow at rest to threaten myocardium. Thrombolytic therapy should also be beneficial in unstable angina by eliminating the thrombus that provokes the acute coronary syndrome.
However, this line of reasoning is flawed. Acute myocardial infarction carries a high mortality rate because needed myocardium is dysfunctional and arrhythmogenic. Unless complicated by acute infarction, unstable angina carries a very low in-hospital mortality rate See p 1407 approximately equal to the incidence of stroke caused by thrombolytic therapy. Treatment of acute infarction must be directed toward opening the coronary occlusion that is producing the life-threatening syndrome. In contrast, the goal of treatment in unstable angina is to prevent new coronary occlusion and consequent myocardial infarction. This situation is analogous to the postthrombolytic phase of myocardial infarction, in which one of the aims is to prevent reocclusion.
Opening a closed artery and keeping an unstable artery open seem to require different tools. Heparin alone is not very effective in rapidly opening total coronary occlusions but almost totally prevents new coronary occlusions in unstable angina: in the study of Theroux et al,' only two of 240 unstable angina patients randomized to heparin developed myocardial infarction during treatment. Aspirin also reduces the incidence of infarction during the acute and chronic phases of un-stable angina.2-4 The success of heparin and aspirin in these clinical trials implies that thrombin generation and platelet aggregation play key roles in the progression of coronary thrombosis to occlusion and thus in determining the outcome of unstable angina. Evidence of platelet aggregation5 and increased thrombin gener-ation6 have been reported in patients with unstable angina.
On the other hand, several pieces of evidence indicate that thrombolytic therapy, although capable of rapidly opening occluded arteries, may set in motion pathophysiological mechanisms that favor further thrombosis. One of these mechanisms is enhanced thrombin formation: markers of thrombin generation such as fibrinopeptide A and thrombin-antithrombin III levels increase after coronary thrombolysis.7-10 The source of this thrombin is unclear. It may originate from the thrombus undergoing lysis, from reexposure of the original thrombogenic surface created by plaque rupture, or from the accelerated generation of new thrombin resulting from the procoagulant effect of plasminogen activators. The plasminogen activators or plasmin may contribute in part to the increased thrombin activity by activating factor V.11 Thrombin is not only a procoagulant but also an important activator of platelets; when unchecked, thrombin may trigger the thrombotic process at the site of plaque rupture. Thrombus formation at the site of arterial injury in the porcine angioplasty model (which simulates plaque rupture) is prevented by the specific thrombin inhibitor hirudin. 12 However, standard heparin therapy may not block the increase in thrombin activity observed during thrombolysis in patients. 10.13 Whether hirudin or the other potent antithrombin Ill-independent antithrombins will be more effective than heparin during thrombolysis remains to be tested in patients.
Thrombolytic therapy also activates platelets. Markers of platelet activation in vivo, such as urinary thromboxane metabolites, have been found to be markedly elevated after thrombolysis,14-16 as is the platelet aggregatory response to different agonists.1617 Although this platelet activation may be secondary to thrombin generation, thrombolytic agents appear both to activate and to inhibit platelets directly, with activation predominating early. Platelets and platelet products are also implicated in reocclusion after thrombolytic therapy for acute infarction, because reocclusion can be prevented in animal models by platelet inhibitors in the absence of thrombin inhibition,1415,1819 and plasmin may activate platelets in vitro despite thrombin inhibition.9 In addition, activated platelets potentiate the coagulation pro-cess and thrombin formation by providing cofactors that increase prothrombinase activity,20,21 and thrombolytic agents at therapeutic doses may increase the ability of platelets to generate thrombin. 9 Activated platelets release vasoactive products such as serotonin and thromboxane A2 that not only amplify the recruitment of other platelets but also induce local vasoconstriction that can be severe enough during thrombolysis to be observed angiographically.22 Likewise, the increased thrombin generation may exert a direct effect on the arterial wall, leading to vasoconstriction.23 Activated platelets can counteract fibrinolysis by releasing plasminogen activator inhibitor from their a-granules and by inactivating plasmin through the release of a2-plasmin.
The outcome of unstable angina depends on the competition between thrombotic and thrombolytic forces at the culprit lesion, and the synergistic effects of the aforementioned mechanisms may tip the balance in favor of thrombosis in some patients.
The Present Study
The study by Schreiber et a124 in this issue of Circulation suggests that some of the mechanisms described above may influence the outcome of unstable angina patients treated with thrombolysis. Within 4 days of presentation, myocardial infarction developed in 10.2% of patients treated with urokinase plus heparin, 6.4% of those treated with urokinase plus aspirin, and 3.8% of those treated with heparin alone. Baseline disparities among the three treatment groups are unlikely to account for these differences. The inability of heparin to prevent infarction in urokinase-treated patients is concordant with the inability of heparin to prevent the urokinase-induced acceleration of thrombin generation in vitro. 9 The sample size of the trial was projected to be 600 patients (200 per group), but the Data Safety Monitoring Board recommended that the trial be terminated after analyzing the results of only the first 150 patients "because of the absence of a trend favoring active therapy." If the results had been the reverse, the trial would have continued, and if the trend had persisted, thrombolytic therapy would have been proclaimed beneficial for unstable angina. It is unfortunate that the Data Safety Monitoring Board terminated the trial so quickly. If the advantage of placebo plus heparin over urokinase plus heparin had persisted and attained statistical significance, this might have become one of the rare, landmark studies, like the Cardiac Arrhythmia Suppression Trial,25 that overturns conventional thinking because the result is not just negative but rather the opposite of what was expected.
Other Studies Nine randomized, controlled clinical trials, including the present one, have assessed thrombolytic therapy in unstable angina,24'26-33 excluding studies published only in abstract form, those without confirmatory coronary arteriography, and those in which patients did not receive intravenous heparin as background therapy. The thrombolytic agent was recombinant tissue-type plasminogen activator (rt-PA) in six trials, 26-30,32 urokinase in two,24'31 and anisoylated plasminogen streptokinase activator complex (APSAC) in one33; the duration of follow-up ranged from 12 to 48 hours to 8 days. Overall, 22 of the 251 patients receiving thrombolysis and 10 of 272 in the control groups (excluding control groups not treated with heparin) developed myocardial infarction. Patients who did not receive study medication and patients with myocardial infarction detected within 24 hours (and presumably present before treatment) in one study33 are not counted in these totals. The relative risk for myocardial infarction with thrombolytic therapy is thus 2.38, but the 95% confidence intervals are wide, 1. 15-4.94 .
The effects of thrombolytic therapy in unstable angina are better defined for the end points that are less important than for the incidence of myocardial infarction. The percent diameter stenosis of the ischemiaproducing artery was reduced by less than 10% with rt-PA in two studies using quantitative measurements. 27, 29 This seemingly small degree of improvement may be of clinical benefit: the ischemic pacing threshold increased significantly, from 112 to 127 beats per minute, in rt-PA-treated patients but not in controls in the study of Nicklas et al. 27 However, this improvement in stenosis severity and ischemic threshold may, paradoxically, coincide with an increased potential for intermittent ischemia; in the study of Freeman et al,32 rt-PA-treated patients had larger resting thallium defects and more episodes of ST segment shifts.
The angiographic findings in patients who present with unstable angina are diverse, and it would not be surprising if thrombolytic therapy proved to be of value in certain subsets. Patients with intracoronary thrombus that can be clearly identified angiographically have been singled out as a group who might be most likely to derive benefit from thrombolysis.
Conclusions
The small-sized clinical trials reported to date raise the suspicion that, compared with heparin alone, thrombolytic therapy for unstable angina may be associated with a higher myocardial infarction rate. Activation of platelets and the plasma coagulation system by thrombolytic therapy could explain this finding. Larger clinical trials, such as the Thrombolysis In Myocardial Ischemia-3 studies, may help to clarify this issue. However, the outlook for thrombolysis in unstable angina has dimmed considerably. The ball game is in the late innings and the home team is losing badly. Soon the meta-analysts will arrive, like sportscasters, to announce the final score.
